Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 4, 1999, Pages 471-479

  Hwang, Clara ^a   Sanda, Martin G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GENE PRODUCT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; VIRUS VACCINE;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; POXVIRUS; PROSTATE CANCER; REVIEW; VACCINIA VIRUS; VIRUS RECOMBINANT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, VIRAL; ANTIGEN PRESENTATION; ANTIGENS, CD80; ANTIGENS, NEOPLASM; AUTOIMMUNITY; CANARYPOX VIRUS; CANCER VACCINES; CELL COMPARTMENTATION; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYTOKINES; DNA, RECOMBINANT; FOWLPOX VIRUS; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; MALE; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; POXVIRIDAE; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RATS; RECOMBINANT FUSION PROTEINS; SALVAGE THERAPY; SELF TOLERANCE; SMALLPOX VACCINE; SPECIES SPECIFICITY; VACCINATION; VACCINIA; VIRAL VACCINES;

ANIMALIA; POXVIRIDAE; VACCINIA; VACCINIA VIRUS;

EID: 0032874885     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Boring CC, Squires TS, Tong T, Montgomery S: Cancer statistics, 1994. CA Cancer J Clin (1994) 44:7-26.
2. Hamby LS, Freeman JW, McGrath PC: Improved survival with adjuvant immunotherapy after surgical resection in a murine model. Ann Surg Oncol (1994) 1:307-313.
3. Pound CR, Partin AW, Epstein JI, Walsh PC: Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am (1997) 24:395-406.
4. Brannen GE, Gomolka DM, Coffey DS: Specificity of cell membrane antigens in prostatic cancer. Cancer Chemother Rep (1975) 59:127-138.
5. Moody DB, Robinson JC, Ewing CM, Lazenby AJ, Isaacs WB: Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo. Prostate (1994) 24:244-251.
6. Vieweg J, Rosenthal FM, Bannerji R, Heston WD, Fair WR, Gansbacher B, Gilboa E: Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res (1994) 54:1760-1765.
7. Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, Dranoff G, Pardoll DM, Mulligan RC, Simons JW: Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol (1994) 151:622-628.
8. Wright P, Zheng C, Moyana T, Xiang J: Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF}-alpha induces significant tumor regression. Cancer Gene Ther (1998) 5:371-379.
9. D'Angelica M, Karpoff H, Halterman M, Ellis J, Klimstra D, Edelstein D, Brownlee M, Federoff H, Fong Y: In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors. Cancer Immunol Immunother (1999) 47:265-271.
10. Leroy P, Slos P, Homann H, Erbs P, Poitevin Y, Regulier E, Colonna FQ, Devauchelle P, Roth C, Pavirani A, Mehtali M: Cancer immunotherapy by direct in vivo transfer of immunomodulatory genes. Res Immunol (1998) 149:681-684.
11. Kawakita M, Rao GS, Ritchey JK, Omstein DK, Hudson MA, Tartaglia J, Paoletti E, Humphrey PA, Harmon TJ, Ratliff TL: Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. J Natl Cancer Inst (1997) 89:428-436.
12. Wang MC, Valenzuela LA, Murphy GP, Chu TM: Purification of a human prostate specific antigen. Invest Urol (1979) 17:159-163.
13. Israeli RS, Powell CT, Fair WR, Heston WD: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res (1993) 53:227-230.
14. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON: Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA (1998) 95:1735-1740.
15. Vihko P, Virkkunen P, Henttu P, Roiko K, Solin T, Huhtala ML: Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase. FEBS Lett (1988) 236:275-281.
16. Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R: Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol (1997) 159:3113-3117.
17. Peshwa MV, Shi JD, Ruegg C, Laus R, van Schooten WC: Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate (1998) 36:129-138.
18. Hodge JW, Schlom J, Donohue SJ, Tomaszewski JE, Wheeler CW, Levine BS, Gritz L, Panicali D, Kantor JA: A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer (1995) 63:231-237.
19. Wei C, Storozynsky E, McAdam AJ, Yeh KY, Tilton BR, Willis RA, Barth RK, Looney RJ, Lord EM, Frelinger JG: Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes. Cancer Immunol Immunother (1996) 42:362-368.
20. Wei C, Willis RA, Tilton BR, Looney RJ, Lord EM, Barth RK, Frelinger JG: Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. Proc Natl Acad Sci USA (1997) 94:6369-6374.
21. Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY: In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst (1997) 89:293-300.
22. Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY: Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol (1998) 161:3186-3194.
23. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A: Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate (1996) 29:371-380.
24. Moss B: Vaccinia virus: a tool for research and vaccine development Science (1991) 252:1662-1667.
25. Panicali D, Paoletti E: Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA (1982) 79:4927-4931.
26. Earl PL, Moss B, Morrison RP, Wehrly K, Nishio J, Chesebro B: T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science (1986) 234:728-731.
27. Lathe R, Kieny MP, Gerlinger P, Clertant P, Guizani I, Cuzin F, Chambon P: Tumour prevention and rejection with recombinant vaccinia. Nature (1987) 326:878-880.
28. Estin CD, Stevenson US, Plowman GD, Hu SL, Sridhar P, Hellström I, Brown JP, Hellstrom KE: Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc Natl Acad Sci USA (1988) 85:1052-1056.
29. Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J: Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst (1992) 84:1084-1091.
30. Wang M, Bronte V, Chen PW, Gritz L, Panicali D, Rosenberg SA, Restifo NP: Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol (1995) 154:4685-4692.
31. Bronte V, Carroll MW, Goletz TJ, Wang M, Overwijk WW, Marincola F, Rosenberg SA, Moss B, Restifo NP: Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci USA (1997) 94:3183-3188.
32. Xie YC, Hwang C, Overwijk W, Zeng Z, Eng MH, Mulé JJ, Imperiale MJ, Restifo NP, Sanda MG: Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen. J Natl Cancer Inst (1999) 91:169-175.
33. Cooney EL, Collier AC, Greenberg PD, Coombs RW, Zarling J, Arditti DE, Hoffman MC, Hu SL, Corey L: Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet (1991) 337:567-572.
34. Baxby D, Paoletti E: Potential use of non-replicating vectors as recombinant vaccines. Vaccine (1992) 10:8-9.
35. Somogyi P, Frazier J, Skinner MA: Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells. Virology (1993) 197:439-444.
36. Taylor J, Weinberg R, Languet B, Desmettre P, Paoletti E: Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine (1988) 6:497-503.
37. Taylor J, Trimarchi C, Weinberg R, Languet B, Guillemin F, Desmettre P, Paoletti E: Efficacy studies on a canarypox-rabies recombinant virus. Vaccine (1991) 9:190-193.
38. Cooney EL, McElrath MJ, Corey L, Hu SL. Collier AC, Arditti D, Huffman M, Coombs RW, Smith GE, Greenberg PD: Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci USA (1993) 90:1882-1886.
39. Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP: Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst (1997) 89:1595-1601.
40. Boon T, Coulie PG, Van den Eynde B: Tumor antigens recognized by T cells. Immunol Today (1997) 18:267-268.
41. Zeh HJ, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC: High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol (1999) 162:989-994.
42. Ludewig B, Odermatt B, Landmann S, Hengartner H, Zinkernagel RM: Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. J Exp Med (1998) 188:1493-1501.
43. Zaks TZ, Rosenberg SA: Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res (1998) 58:4902-4908.
44. Bohm CM, Hanski ML, Stefanovic S, Rammensee HG, Stein H, Taylor-Papadimitriou J, Riecken EO, Hanski C: Identification of HLA-A2-restricted epitopes of the tumor-associated antigen MUC2 recognized by human cytotoxic T cells. Int J Cancer (1998) 75:688-693.
45. Akagi J, Nakagawa K, Egami H, Ogawa M: Induction of HLA-unrestricted and HLA-class-II-restricted cytotoxic T lymphocytes against MUC-1 from patients with colorectal carcinomas using recombinant MUC-1 vaccinia virus. Cancer Immunol Immunother (1998) 47:21-31.
46. Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner JW: Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res (1999) 59:676-683.
47. Morgan DJ, Kreuwel HT, Fleck S, Levitsky HI, Pardoll DM, Sherman LA: Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol (1998) 160:643-651.
48. Sanda MG, Smith DC, Charles LG, Hwang C, Pienta KJ, Schlom J, Milenic D, Panicali D, Montie JE: Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology (1999) 53:260-266.
49. Chen AP, Bastian A, Dahut W, Chung Y, Tsang K, Khleif S, Blake K, Gelmann E, Marshall J, Schlom J, Allegra C, Hamilton JM: A phase I study of recombinant vaccinia virus (RV) that expresses prostate specific antigen (PSA) in adult patients (PTS) with adenocarcinoma of the prostate. Proc Am Soc Clin Oncol (1998) 17:314a.
50. Eder JP Jr, Kantoff PW, Bubley GJ, O'Connor LA, Rodriguez D, Xu G, Tsang A, Schlom J, Mazzara G, Panicali D, Horzempa ML, Kufe DW: A phase I trial of recombinant vaccinia virus, prostvac that expresses prostate specific antigen (rV-PSA) as a vaccine in men with advanced prostate cancer. Proc Am Soc Clin Oncol (1998) 17:434a.
51. Tartaglia J, Pincus S, Paoletti E: Poxvirus-based vectors as vaccine candidates. Crit Rev Immunol (1990) 10:13-30.
52. Coupar BE, Andrew ME, Both GW, Boyle DB: Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. Eur J Immunol (1986) 16:1479-1487.
53. Townsend A, Bastin J, Gould K, Brownlee G, Andrew M, Coupar B, Boyle D, Chan S, Smith G: Defective presentation to class l-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J Exp Med (1988) 168:1211-1224.
54. Wachsman M, Luo JH, Aurelian L, Perkus ME, Paoletti E: Antigen-presenting capacity of epidermal cells infected with vaccinia virus recombinants containing the herpes simplex virus glycoprotein D, and protective immunity. J Gen Virol (1989) 70:2513-2520.
55. Lewis PJ, Cox GJ, van Drunen Littel-van den Hurk S, Babiuk LA: Polynucleotide vaccines in animals: enhancing and modulating responses. Vaccine (1997) 15:861-864.
56. Yewdell JW, Bennink JR: Antigen processing: a critical factor in rational vaccine design. Semin Hematol (1993) 30:26-34.
57. Tobery T, Siliciano RF: Induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen. J Immunol (1999) 162:639-642.
58. Fu TM, Mylin LM, Schell TD, Bacik I, Russ G, Yewdell JW, Bennink JR, Tevethia SS: An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. J Virol (1998) 72:1469-1481.
59. Restifo NP, Bacík I, Irvine KR, Yewdell JW, McCabe BJ, Anderson RW, Eisenlohr LC, Rosenberg SA, Bennink JR: Antigen processing in vivo and the elicitation of primary CTL responses. J Immunol (1995) 154:4414-4422.
60. Irvine KR, McCabe BJ, Rosenberg SA, Restifo NP: Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. J Immunol (1995) 154:4651-4657.
61. McLaughlin JP, Schlom J, Kantor JA, Greiner JW: Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res (1996) 56:2361-2367.
62. Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, Restifo NP: IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol (1995) 154:5282-5292.
63. Carroll MW, Overwijk WW, Surman DR, Tsung K, Moss B, Restifo NP: Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen. J Natl Cancer Inst (1998) 90:1881-1887.
64. Sivanandham M, Scoggin SD, Tanaka N, Wallack MK: Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model. Cancer Immunol Immunother (1994) 38:259-264.
65. Sivanandham M, Shaw P, Bemik SF, Paoletti E, Wallack MK: Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice. Cancer Immunol Immunother (1998) 46:261-267.
66. Chamberlain RS, Carroll MW, Bronte V, Hwu P, Warren S, Yang JC, Nishimura M, Moss B, Rosenberg SA, Restifo NP: Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res (1996) 56:2832-2836.
67. Hodge JW, Abrams S, Schlom J, Kantor JA: Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res (1994) 54:5552-5555.
68. Meko JB, Tsung K, Norton JA: Cytokine production and antitumor effect of a nonreplicating, noncytopathic recombinant vaccinia virus expressing interleukin-12. Surgery (1996) 120:274-282; discussion 282-283.
69. Qin H, Chatterjee SK: Recombinant vaccinia expressing Interleukin-2 for cancer gene therapy. Cancer Gene Ther (1996) 3:163-167.
70. Qin HX, Chatterjee SK: Construction of recombinant vaccinia virus expressing GM-CSF and its use as tumor vaccine. Gene Ther (1996) 3:59-66.
71. Qin H, Chatterjee SK: Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. Hum Gene Ther (1996) 7:1853-1860.
72. Smith GL, Moss B: Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene (1983) 25:21-28.
73. Zajac P, Schutz A, Oertli D, Noppen C, Schaefer C, Heberer M, Spagnoli GC, Marti WR: Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules. Cancer Res (1998) 58:4567-4571.